[In-vitro study of the drug interactions between Miglitol, an alpha-glucosidase inhibitor, and adsorbents].
The interactions between miglitol, an alpha-glucosidase inhibitor, and six adsorbents (carbon spheres, cholestyramine, colestimide, sevelamer hydrochloride, calcium polystyrene sulfonate, and sodium polystyrene sulfonate) were investigated in vitro. Miglitol corresponding to the minimum dose and adsorbents corresponding to the maximum dose were incubated at 37 degrees C for 180 min in solutions of pH 1.2 (gastric pH condition) and pH 6.8 (enteric pH condition), with and without the presence of carbohydrates, which were added to observe the effects on food adsorption. The adsorption ratio of miglitol to carbon spheres was 13.6% and 0% in pH 1.2 solution and 86.4% and 5.0% in pH 6.8 solution without and with the presence of carbohydrates, respectively. Thus, the adsorption ratio was higher in pH 6.8 solution. Adsorption of miglitol to calcium polystyrene sulfonate was nearly the same, 15.0-21.9%, at both pH. The adsorption ratio of miglitol to sodium polystyrene sulfonate was 43.4% and 45.5%, respectively, in pH 1.2 solution without and with carbohydrates. In the pH 6.8 solutions, however, the respective adsorption ratios were low (5.2% and 11.3%). Miglitol did not adsorb to cholestyramine, sevelamer hydrochloride or colestimide under any pH condition examined. The above results suggest that miglitol adsorbs to carbon spheres and polystyrene sulfonic acid cation exchange resins. However, considering that miglitol is taken just before eating and thus exists in gastointestinal fluids together with food, and that the site of its effect is the upper small intestine, the interactions between miglitol and these adsorbents will most likely not be a problem.
Amioka
Katsuo
K
Clinical Pharmacy, College of Pharmacy, Kinjo Gakuin University, 2-1723 Oomori, Moriyama-ku, Nagoya 463-8521, Japan.
Wada
Ikuo
I
Furuta
Yoshiyuki
Y
D017485:1-Deoxynojirimycin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D000327:Adsorption; D002241:Carbohydrates; D002244:Carbon; D002411:Cation Exchange Resins; D002792:Cholestyramine Resin; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics; D004811:Epichlorohydrin; D065089:Glycoside Hydrolase Inhibitors; D006863:Hydrogen-Ion Concentration; D007004:Hypoglycemic Agents; D007093:Imidazoles; D050112:Imino Pyranoses / Q000493:pharmacokinetics; D066298:In Vitro Techniques; D011073:Polyamines; D011137:Polystyrenes; D012117:Resins, Synthetic; D000069603:Sevelamer
D002241:Carbohydrates; D002411:Cation Exchange Resins; D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D007093:Imidazoles; D050112:Imino Pyranoses; D011073:Polyamines; D011137:Polystyrenes; D012117:Resins, Synthetic; C417427:colestimide; D004811:Epichlorohydrin; C045621:miglitol; D002792:Cholestyramine Resin; D017485:1-Deoxynojirimycin; C003321:polystyrene sulfonic acid; D002244:Carbon; D000069603:Sevelamer